OBJECTIVE: To assess neurocognitive outcomes following antipsychotic intervention in youth enrolled in the National Institute of Mental Health (NIMH)-funded Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS). METHOD:Neurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone. The primary outcomes were overall group change from baseline in neurocognitive composite and six domain scores after 8 weeks and continued treatment up to 52 weeks. Age and sex were included as covariates in all analyses. RESULTS:Of 116 TEOSS participants, 77 (66%) had post-baseline neurocognitive data. No significant differences emerged in the neurocognitive outcomes of the three medication groups. Therefore, the three treatment groups were combined into one group to assess overall neurocognitive outcomes. Significant modest improvements were observed in the composite score and in three of six domain scores in the acute phase, and in four of six domain scores in the combined acute and maintenance phases. Partial correlation analyses revealed very few relationships among Positive and Negative Syndrome Scale (PANSS) baseline or change scores and neurocognition change scores. CONCLUSIONS:Antipsychotic intervention in youth with early-onset schizophrenia spectrum disorders (EOSS) led to modest improvement in measures of neurocognitive function. The changes in cognition were largely unrelated to baseline symptoms or symptom change. Small treatment effect sizes, easily accounted for by practice effects, highlight the critical need for the development of more efficacious interventions for the enduring neurocognitive deficits seen in EOSS. Clinical trial registry information-Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS); http://www.clinicaltrials.gov; NCT00053703.
RCT Entities:
OBJECTIVE: To assess neurocognitive outcomes following antipsychotic intervention in youth enrolled in the National Institute of Mental Health (NIMH)-funded Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS). METHOD: Neurocognitive functioning of youth (ages 8 to 19 years) with schizophrenia or schizoaffective disorder was evaluated in a four-site, randomized, double-blind clinical trial comparing molindone, olanzapine, and risperidone. The primary outcomes were overall group change from baseline in neurocognitive composite and six domain scores after 8 weeks and continued treatment up to 52 weeks. Age and sex were included as covariates in all analyses. RESULTS: Of 116 TEOSS participants, 77 (66%) had post-baseline neurocognitive data. No significant differences emerged in the neurocognitive outcomes of the three medication groups. Therefore, the three treatment groups were combined into one group to assess overall neurocognitive outcomes. Significant modest improvements were observed in the composite score and in three of six domain scores in the acute phase, and in four of six domain scores in the combined acute and maintenance phases. Partial correlation analyses revealed very few relationships among Positive and Negative Syndrome Scale (PANSS) baseline or change scores and neurocognition change scores. CONCLUSIONS: Antipsychotic intervention in youth with early-onset schizophrenia spectrum disorders (EOSS) led to modest improvement in measures of neurocognitive function. The changes in cognition were largely unrelated to baseline symptoms or symptom change. Small treatment effect sizes, easily accounted for by practice effects, highlight the critical need for the development of more efficacious interventions for the enduring neurocognitive deficits seen in EOSS. Clinical trial registry information-Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS); http://www.clinicaltrials.gov; NCT00053703.
Authors: Dawn I Velligan; Thomas J Prihoda; Janice L Ritch; Natalie Maples; C Christine Bow-Thomas; Albana Dassori Journal: Schizophr Bull Date: 2002 Impact factor: 9.306
Authors: R M Bilder; R S Goldman; D Robinson; G Reiter; L Bell; J A Bates; E Pappadopulos; D F Willson; J M Alvir; M G Woerner; S Geisler; J M Kane; J A Lieberman Journal: Am J Psychiatry Date: 2000-04 Impact factor: 18.112
Authors: Jon McCLELLAN; Linmarie Sikich; Robert L Findling; Jean A Frazier; Benedetto Vitiello; Stefanie A Hlastala; Emily Williams; Denisse Ambler; Tyehimba Hunt-Harrison; Ann E Maloney; Louise Ritz; Robert Anderson; Robert M Hamer; Jeffrey A Lieberman Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-08 Impact factor: 8.829
Authors: Alysa E Doyle; Pieter J Vuijk; Nathan D Doty; Lauren M McGrath; Brian L Willoughby; Ellen H O'Donnell; H Kent Wilson; Mary K Colvin; Deanna C Toner; Kelsey E Hudson; Jessica E Blais; Hillary L Ditmars; Stephen V Faraone; Larry J Seidman; Ellen B Braaten Journal: J Int Neuropsychol Soc Date: 2017-08-04 Impact factor: 2.892
Authors: Robert L Findling; Ronald P Landbloom; Mary Mackle; Wendi Pallozzi; Sabine Braat; Carla Hundt; Marianne Z Wamboldt; Maju Mathews Journal: J Child Adolesc Psychopharmacol Date: 2015-06 Impact factor: 2.576
Authors: Cristan A Farmer; Jeffery N Epstein; Robert L Findling; Kenneth D Gadow; L Eugene Arnold; Heidi Kipp; David J Kolko; Eric Butter; Jayne Schneider; Oscar G Bukstein; Nora K McNamara; Brooke S G Molina; Michael G Aman Journal: J Child Adolesc Psychopharmacol Date: 2016-06-27 Impact factor: 2.576
Authors: Jerome H Taylor; Scott Appel; Matthew Eli; Aaron Alexander-Bloch; Lawrence Maayan; Raquel E Gur; Michael H Bloch Journal: J Child Adolesc Psychopharmacol Date: 2020-07-01 Impact factor: 2.576
Authors: Anne Katrine Pagsberg; Pia Jeppesen; Dea Gowers Klauber; Karsten Gjessing Jensen; Ditte Rudå; Marie Stentebjerg-Olesen; Peter Jantzen; Simone Rasmussen; Eva Ann-Sofie Saldeen; Maj-Britt Glenn Lauritsen; Niels Bilenberg; Anne Dorte Stenstrøm; Jesper Pedersen; Louise Nyvang; Sarah Madsen; Marlene B Lauritsen; Ditte Lammers Vernal; Per Hove Thomsen; Jakob Paludan; Thomas M Werge; Kristian Winge; Klaus Juul; Christian Gluud; Maria Skoog; Jørn Wetterslev; Jens Richardt M Jepsen; Christoph U Correll; Anders Fink-Jensen; Birgitte Fagerlund Journal: BMC Psychiatry Date: 2014-07-11 Impact factor: 3.630